Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease | Zendy

William H. Herman | Zendy; Shahnaz Shahinfar | Zendy; George W. Carides | Zendy; Erik J. Dasbach | Zendy; William C. Gerth | Zendy; Charles M. Alexander | Zendy; J.R. Cook | Zendy; William F. Keane | Zendy; Barry M. Brenner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease

Author(s) -

William H. Herman,

Shahnaz Shahinfar,

George W. Carides,

Erik J. Dasbach,

William C. Gerth,

Charles M. Alexander,

J.R. Cook,

William F. Keane,

Barry M. Brenner

Publication year - 2003

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/diacare.26.3.683

Subject(s) - medicine , losartan , diabetes mellitus , end stage renal disease , disease , urology , stage (stratigraphy) , kidney disease , endocrinology , intensive care medicine , renin–angiotensin system , blood pressure , paleontology , biology

To evaluate the within-trial effect of losartan and conventional antihypertensive therapy (CT) compared with placebo and CT on the economic cost associated with end-stage renal disease (ESRD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research